EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Exploring the therapeutic potential of precision medicine in rare genetic obesity disorders: a scientific perspective

Tinh-Hai Collet, Valerie Schwitzgebel

Frontiers in Nutrition · 23.12.2024 · 11

DOI: 10.3389/fnut.2024.1509994 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Nutrition, online erschienen am 23.12.2024. Verfasst von Tinh-Hai Collet und 1 weiteren Autor:innen. Beteiligte Einrichtung: Service of Endocrinology, Diabetes, Nutrition, and Therapeutic Education, Geneva University Hospitals, Geneva, Switzerland. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of obesity is increasing worldwide, affecting both children and adults. This obesity epidemic is mostly driven by an increase in energy intake (abundance of highly palatable energy-dense food and drinks) and to a lesser degree a decrease in energy expenditure (sedentary lifestyle). A small proportion of individuals with obesity are affected by genetic forms of obesity, which often relate to mutations in the leptin-melanocortin pathway or are part of syndromes such as the Bardet-Biedl syndrome. These rare forms of obesity have provided valuable insights into the genetic architecture of obesity. Recent advances in understanding the molecular mechanisms that control appetite, hunger, and satiety have led to the development of drugs that can override genetic defects, enabling precision treatment. Leptin deficiency is uniquely treated with recombinant human metreleptin, while those with LEPR, PCSK1, or POMC deficiency can now be treated with the MC4R agonist setmelanotide. This review highlights the most frequent monogenic and syndromic forms of obesity, and the future outlook of precision treatment for these conditions.

Schlagwörter

Stichwörter der Autor:innen

Bardet-Biedel syndromeleptin receptor (LEPR)leptin-melanocortin pathwaymelanocortin-4 receptor (MC4R)monogenic obesityprecision medicinepro-opio-melanocortin (POMC)proprotein convertase subtilisin/kexin-type 1 (PCSK1)

Autor:innen und Institutionen

  • Service of Endocrinology, Diabetes, Nutrition, and Therapeutic Education, Geneva University Hospitals, Geneva, Switzerland.
  • Faculty of Medicine, Diabetes Center, University of Geneva, Geneva, Switzerland.
  • Pediatric Endocrine and Diabetes Unit, Department of Pediatrics, Obstetrics, and Gynecology, Geneva University Hospitals, Geneva, Switzerland.
  • Institute of Genetics and Genomics in Geneva (iGE3), University of Geneva, Geneva, Switzerland.

Zitieren

APA

Collet, T. H., & Schwitzgebel, V. (2024). Exploring the therapeutic potential of precision medicine in rare genetic obesity disorders: a scientific perspective. Frontiers in Nutrition, 11. https://doi.org/10.3389/fnut.2024.1509994

Vancouver

Collet TH, Schwitzgebel V. Exploring the therapeutic potential of precision medicine in rare genetic obesity disorders: a scientific perspective. Frontiers in Nutrition. 2024;11. doi:10.3389/fnut.2024.1509994

BibTeX
@article{Collet2024,
  author = {Collet, Tinh-Hai and Schwitzgebel, Valerie},
  title = {Exploring the therapeutic potential of precision medicine in rare genetic obesity disorders: a scientific perspective},
  journal = {Frontiers in Nutrition},
  year = {2024},
  volume = {11},
  doi = {10.3389/fnut.2024.1509994}
}
Kostenlos starten →